{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T18:32:29Z","timestamp":1788892349954,"version":"build-2803163510"},"reference-count":21,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Acquired hemophilia A (AHA) is a rare, life-threatening autoimmune disorder characterized by inhibitory autoantibodies against factor VIII (FVIII), resulting in spontaneous or trauma-related bleeding. This study reviews a single-center cohort to evaluate patient characteristics, treatments, and outcomes. Methods: We retrospectively reviewed the records of 22 adult patients diagnosed with AHA between 2012 and 2024. The data included demographics, clinical presentation, laboratory findings, treatments, and outcomes. Statistical analysis compared genders and evaluated treatment strategies and remission outcomes. Results: The cohort had an equal gender distribution with an average age of 62 years (22\u2013102 years). Suspected etiologies included pregnancy (27%), malignancy (23%), autoimmune diseases (5%), and idiopathic causes (45%). The most common presentation was spontaneous cutaneous hematoma (82%). Severe bleeding necessitating hemostatic therapy occurred in 9% of cases. Initial immunosuppressive therapy (IST) with corticosteroids achieved remission in 45% of patients, while additional treatment with Rituximab or Cyclophosphamide was required in others. Emicizumab, a novel FVIII-mimetic, was successfully used in one patient with severe refractory bleeding. Remission was achieved in 64% of patients within a median of 3 months, with a recurrence rate of 14%. No thrombotic events were observed, although corticosteroid side effects, including one hip fracture, were noted. Conclusions: IST remains the cornerstone of AHA treatment, though side effects necessitate individualized care. Emicizumab shows promise, particularly in refractory cases and fragile populations. Future research is needed to evaluate long-term outcomes and spontaneous remission rates, especially in special populations like post-partum women and the elderly.<\/jats:p>","DOI":"10.3390\/jcm14051597","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T03:37:57Z","timestamp":1740627477000},"page":"1597","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Acquired Hemophilia\u2014A Case Series and Review"],"prefix":"10.3390","volume":"14","author":[{"given":"Liat","family":"Waldman Radinsky","sequence":"first","affiliation":[{"name":"National Hemophilia Center, Sheba Medical Center, Ramat-Gan 5266202, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maayan","family":"Sivan","sequence":"additional","affiliation":[{"name":"Sheba Medical Center, Ramat-Gan 5266202, Israel"},{"name":"Medical School, University of Nicosia, 2408 Nicosia, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aharon","family":"Lubetsky","sequence":"additional","affiliation":[{"name":"National Hemophilia Center, Sheba Medical Center, Ramat-Gan 5266202, Israel"},{"name":"Faculty of Medical & Health Sciences, Tel-Aviv University, Tel-Aviv 6997801, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mudi","family":"Misgav","sequence":"additional","affiliation":[{"name":"National Hemophilia Center, Sheba Medical Center, Ramat-Gan 5266202, Israel"},{"name":"Faculty of Medical & Health Sciences, Tel-Aviv University, Tel-Aviv 6997801, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shadan","family":"Lalezari","sequence":"additional","affiliation":[{"name":"National Hemophilia Center, Sheba Medical Center, Ramat-Gan 5266202, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omri","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine, Kaplan Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 7661041, Israel"},{"name":"Department of Medicine and Surgery, University of Insubria, 21100 Varese, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tlalit","family":"Barhod","sequence":"additional","affiliation":[{"name":"National Hemophilia Center, Sheba Medical Center, Ramat-Gan 5266202, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3494-9823","authenticated-orcid":false,"given":"Gili","family":"Kenet","sequence":"additional","affiliation":[{"name":"National Hemophilia Center, Sheba Medical Center, Ramat-Gan 5266202, Israel"},{"name":"Faculty of Medical & Health Sciences, Tel-Aviv University, Tel-Aviv 6997801, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orly","family":"Efros","sequence":"additional","affiliation":[{"name":"National Hemophilia Center, Sheba Medical Center, Ramat-Gan 5266202, Israel"},{"name":"Faculty of Medical & Health Sciences, Tel-Aviv University, Tel-Aviv 6997801, Israel"},{"name":"Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 7610001, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Zanon, E. (2023). Acquired Hemophilia A: An Update on the Etiopathogenesis, Diagnosis, and Treatment. Diagnostics, 13.","DOI":"10.3390\/diagnostics13030420"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Lehoczki, A., Fekete, M., Mikala, G., and Bod\u00f3, I. (2024). Acquired hemophilia A as a disease of the elderly: A comprehensive review of epidemiology, pathogenesis, and novel therapy. GeroScience, 1\u201312.","DOI":"10.1007\/s11357-024-01317-7"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.3324\/haematol.2019.230771","article-title":"International recommendations on the diagnosis and treatment of acquired hemophilia A","volume":"105","author":"Tiede","year":"2020","journal-title":"Haematologica"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1016\/S0049-3848(12)70019-1","article-title":"Acquired hemophilia in malignancy","volume":"129","author":"Reeves","year":"2012","journal-title":"Thromb. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1177\/107602960000600206","article-title":"Acquired hemophilia A in women postpartum: Clinical manifestations, diagnosis, and treatment","volume":"6","author":"Michiels","year":"2000","journal-title":"Clin. Appl. Thromb."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/ajh.20702","article-title":"Postpartum acquired factor VIII inhibitors","volume":"81","author":"Franchini","year":"2006","journal-title":"Am. J. Hematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1365-2516.2009.02049.x","article-title":"Transplacental transfer of postpartum inhibitors to factor VIII","volume":"16","author":"Lulla","year":"2010","journal-title":"Haemophilia"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/hae.14692","article-title":"Drug-associated acquired hemophilia A: An analysis based on 185 cases from the WHO pharmacovigilance database","volume":"29","author":"Konstantinov","year":"2023","journal-title":"Haemophilia"},{"key":"ref_9","first-page":"549","article-title":"Emicizumab in acquired hemophilia A: Pros and cons of a new approach to the prevention and treatment of bleeding","volume":"21","author":"Pasca","year":"2023","journal-title":"Blood Transfus."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1016\/j.jtha.2024.06.010","article-title":"Emicizumab versus immunosuppressive therapy for the management of acquired hemophilia A","volume":"22","author":"Hart","year":"2024","journal-title":"J. Thromb. Haemost."},{"key":"ref_11","first-page":"1334","article-title":"Emicizumab: The hemophilia A game changer","volume":"109","author":"Andrade","year":"2024","journal-title":"Haematologica"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1111\/hae.15037","article-title":"Acquired haemophilia A in Finland: A nationwide study of incidence, treatment and outcomes","volume":"30","author":"Nummi","year":"2024","journal-title":"Haemophilia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.thromres.2024.03.012","article-title":"Cyclophosphamide vs Rituximab for eradicating inhibitors in acquired hemophilia A: A randomized trial in 108 patients","volume":"237","author":"Viallard","year":"2024","journal-title":"Thromb. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1001\/archinte.1987.00370060073014","article-title":"Acquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy","volume":"147","author":"Lottenberg","year":"1987","journal-title":"Arch. Intern. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-0038-1651666","article-title":"Post-partum factor VIII inhibitors. A review of the literature with special reference to the value of steroid and immunosuppressive treatment","volume":"73","author":"Hauser","year":"1995","journal-title":"Thromb. Haemost."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2012-02-408930","article-title":"Management of bleeding in acquired hemophilia A: Results from the European Acquired Haemophilia (EACH2) Registry","volume":"120","author":"Baudo","year":"2012","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"100027","DOI":"10.1016\/j.bvth.2024.100027","article-title":"Clinical characteristics and outcomes of acquired hemophilia A before and after emicizumab approval in Japan","volume":"1","author":"Kishi","year":"2024","journal-title":"Blood Vessel. Thromb. Hemost."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/blood.2020006315","article-title":"Emicizumab for the treatment of acquired hemophilia A","volume":"137","author":"Knoebl","year":"2021","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e913","DOI":"10.1016\/S2352-3026(23)00280-6","article-title":"Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): An open-label, single-arm, multicentre, phase 2 study","volume":"10","author":"Tiede","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jtha.2022.10.004","article-title":"A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A","volume":"21","author":"Shima","year":"2023","journal-title":"J. Thromb. Haemost."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1055\/a-2197-9738","article-title":"Emicizumab for the Treatment of Acquired Hemophilia A: Consensus Recommendations from the GTH-AHA Working Group","volume":"44","author":"Pfrepper","year":"2024","journal-title":"Hamostaseologie"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/5\/1597\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:43:33Z","timestamp":1760028213000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/5\/1597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,26]]},"references-count":21,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["jcm14051597"],"URL":"https:\/\/doi.org\/10.3390\/jcm14051597","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,26]]}}}